<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04331275</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0042</org_study_id>
    <nct_id>NCT04331275</nct_id>
  </id_info>
  <brief_title>Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant</brief_title>
  <official_title>Viral Specific T-cells (VSTs) for Treatment of Viral Infections After Solid Organ Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoxworth Blood Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn more about the use of viral specific&#xD;
      T-lymphocytes (VSTs) to treat viral infections that may happen after solid organ transplant&#xD;
      (SOT). VSTs are cells specially designed to fight viral infections that may happen after a&#xD;
      solid organ transplant. These cells are created from a blood sample collected from the study&#xD;
      participant.&#xD;
&#xD;
      Solid organ transplant and the use of immunosuppressive medications reduces the body's&#xD;
      ability to fight infections. Viral infections are a common problem after transplant and can&#xD;
      cause significant complications. Reduction of immunosuppression may put the organ at risk of&#xD;
      rejection. Moreover, treatment of viral infections is expensive and time consuming, with&#xD;
      families often administering prolonged treatments with intravenous anti-viral medications, or&#xD;
      patients requiring prolonged admissions to the hospital. The medicines can also have side&#xD;
      effects like damage to the kidneys or reduction in the blood counts, so in this study the&#xD;
      investigators are trying to find a better way to treat these infections and minimize&#xD;
      complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2020</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful production of viral specific T-cells</measure>
    <time_frame>Within 30 days post culture initiation</time_frame>
    <description>Of the patients who had a VST culture initiated, successful production of VST cells is defined as meeting the protocol-defined release criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of viral-specific T-cells</measure>
    <time_frame>At 30 days after infusion</time_frame>
    <description>Presence of viral-specific T-cells in the participant's blood will be assessed by Elispot assay</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Solid Organ Transplant</condition>
  <condition>Viral Infection</condition>
  <arm_group>
    <arm_group_label>Viral Specific T-cells (VSTs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Viral Specific T-cells (VSTs)</intervention_name>
    <description>VSTs will be infused into solid organ transplant recipients who have evidence of viral infection.</description>
    <arm_group_label>Viral Specific T-cells (VSTs)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Blood adenovirus PCR ≥1,000&#xD;
&#xD;
          -  Blood CMV PCR ≥ 500&#xD;
&#xD;
          -  Blood EBV PCR ≥ 1,000&#xD;
&#xD;
          -  Plasma BKV PCR &gt;1,000&#xD;
&#xD;
          -  Plasma JC Virus PCR &gt; 1,000&#xD;
&#xD;
          -  Evidence of invasive adenovirus infection. Adenovirus infection will be defined as the&#xD;
             presence of adenoviral positivity as detected by PCR or culture from one site such as&#xD;
             stool or blood or urine or nasopharynx. Adenovirus disease will be defined as the&#xD;
             presence of adenoviral positivity as detected by culture or PCR from more than 2 sites&#xD;
             such as stool or blood or urine or nasopharynx.&#xD;
&#xD;
          -  Evidence of invasive CMV infection, e.g. pneumonitis, retinitis, colitis.&#xD;
&#xD;
          -  Evidence of EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by&#xD;
             biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood&#xD;
             associated with clinical symptoms (adenopathy or fever or masses on imaging) but&#xD;
             without biopsy confirmation.&#xD;
&#xD;
          -  Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic&#xD;
             cystitis, BK viruria or BK nephropathy&#xD;
&#xD;
          -  Evidence of PML or other CNS infection due to JC virus&#xD;
&#xD;
          -  Clinical status must allow tapering of steroids to &lt; 0.5mg/kg prednisone or other&#xD;
             steroid equivalent, or a clinically acceptable steroid dose at the discretion of the&#xD;
             PI&#xD;
&#xD;
          -  Age &gt; 1 day&#xD;
&#xD;
          -  Must be able to receive VST infusion in Cincinnati&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled bacterial or fungal infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stella Davies, MBBS, PhD, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawn Thomas, BSN, RN</last_name>
    <phone>513-226-5603</phone>
    <email>Shawn.Thomas@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jamie Wilhelm, BS</last_name>
    <phone>513-803-1102</phone>
    <email>Jamie.Wilhelm@cchmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawn Thomas, BSN, RN</last_name>
      <phone>513-226-5603</phone>
      <email>Shawn.Thomas@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Stella Davies, MBBS, PhD, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

